Insuman Basal (Insulin Human)

Insulin human mimics the action of natural human insulin by binding to insulin receptors on muscle, fat and liver cells. This binding activates intracellular pathways that increase glucose uptake, promote glycogen storage, and suppress hepatic glucose production, thereby lowering circulating blood glucose concentrations.

The dose of Insuman Basal is individualized. A qualified prescriber determines the appropriate amount based on the patient’s current glucose profile, body weight, renal function and other clinical factors. Patients should follow the dosing instructions provided by their healthcare professional and adjust only under medical supervision.

The safety of Insuman Basal in pregnancy and lactation has not been definitively established. It may be used when the expected benefit outweighs potential risks, and only under the guidance of an obstetrician or endocrinologist experienced in managing diabetes during pregnancy or while nursing.

To place an order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide. After verification of trade or institutional credentials, the sales team will provide pricing, availability, shipping details—including cold‑chain handling if needed—and assist with any required import documentation.

Insuman Basal contains insulin human, a recombinant human insulin, whereas many newer basal insulins are insulin analogues with modified amino‑acid sequences designed for flatter pharmacokinetic profiles. Both provide long‑duration glucose control, but analogue insulins may have reduced variability and lower nocturnal hypoglycemia risk. Choice depends on clinical response, cost considerations and prescriber preference.

Insuman Basal should be stored at 2‑8 °C (refrigerated) and protected from light. Do not freeze the vial or shake it vigorously. Once opened, the suspension can be kept at refrigerated temperature for up to 28 days, after which any remaining product should be discarded.

Insuman Basal is administered by subcutaneous injection, typically into the abdomen, thigh or upper arm. The injection should be given once daily at the same time each day, using a suitable insulin syringe or pen compatible with the vial. Proper injection technique and site rotation help minimize local reactions.

The most serious risks include severe hypoglycemia, which can cause loss of consciousness or seizures, and rare allergic reactions such as anaphylaxis. Patients should be educated on early signs of low blood glucose and instructed to seek immediate medical attention if they experience symptoms of a severe allergic response.

Insuman Basal is contraindicated in individuals with a known hypersensitivity to insulin human or any excipients in the formulation. It should also be avoided in patients with severe hypoglycemia unawareness unless closely supervised, and in those with acute insulin overdose until the condition is medically managed.